---
schema_version: "secwatch.filing_event.v1"
accession: "0001689548-23-000043"
form_type: "8-K"
ticker: "PRAX"
cik: "0001689548"
company_name: "Praxis Precision Medicines, Inc."
filed_at: "2023-02-07T23:59:59+00:00"
generated_at: "2026-06-19T23:00:00.911668+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Praxis reports FY2022 net loss $214M; cash $100.5M, runway into 1Q24

## Summary
- Cash and investments $100.5M as of Dec 31, 2022, down from $275.9M; expected to fund ops into 1Q24.
- Net loss FY2022 $214.0M vs $167.1M; Q4 net loss $41.2M.
- R&D expense FY2022 $155.0M, up from $120.3M, reflecting Cerebrum/Solidus platform spending.
- Phase 2b ulixacaltamide topline results for essential tremor expected in 1Q23.
- Entered UCB collaboration for KCNT1 program; up to ~$100M in milestones plus royalties.

## SEC filing metadata
- accession: 0001689548-23-000043
- form_type: 8-K
- ticker: PRAX
- cik: 0001689548
- company_name: Praxis Precision Medicines, Inc.
- filed_at: 2023-02-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689548/000168954823000043/0001689548-23-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689548/000168954823000043/prax-20230207.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689548-23-000043
- JSON: https://secwatch.observer/filing/0001689548-23-000043.json
- Plain text: https://secwatch.observer/filing/0001689548-23-000043.txt

## Key facts
- Earnings Releases
  Praxis Precision Medicines, Inc. reported financial results for fourth quarter and full year 2022.
  - Period: fourth quarter and full year 2022
  - Result: reported results
  source text: On February 7, 2023 , Praxis Precision Medicines, Inc. (the “Company”) announced its financial results for the quarter and full year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1689548/000168954823000043/0001689548-23-000043-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.